Dr. Wenham on Future Directions with Antibody-Drug Conjugates in Ovarian Cancer

Video

In Partnership With:

Robert Wenham, MD, MS, FACOG, FACS, discusses future directions with antibody-drug conjugates in the treatment of patients with ovarian cancer.

Robert Wenham, MD, MS, FACOG, FACS, a gynecologic oncologist and chair of the Gynecologic Oncology Program at Moffitt Cancer Center, discusses future directions with antibody-drug conjugates (ADCs) in the treatment of patients with ovarian cancer.

ADCs are a key focus for research in ovarian cancer, Wenham says. If a selective target can be identified on a cancer cell, a very toxic payload can be delivered in a way that had not been previously possible, leading to greater efficacy, which makes the use of ADCs attractive, Wenham explains. This has been examined in early studies, specifically folate receptor α (FRα), Wenham notes.

Currently, several studies are examining ADCs are ongoing, most of which are utilizing microtubule-disrupting agents, as their payload can target a host of different targets like MUC, mesothelin, tissue factor, FRα, and TIM-1, Wenham says. However, none of these targets are standard and still need to be properly examined, Wenham concludes.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
A panel of 6 experts on colorectal cancer